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ABSTRACT
Background. Neoadjuvant chemotherapy (NeoCTx) is
performed for most patients with colorectal cancer liver
metastases (CRCLM). However, chemotherapy-associated
liver injury (CALI) has been associated with poor post-
operative outcome. To date, however, no clinically
applicable and noninvasive tool exists to assess CALI
before liver resection.
Methods. Routine blood parameters were assessed in 339
patients before and after completion of NeoCTx and before
surgery. The study assessed the prognostic potential of the
aspartate aminotransferase (AST)-to-platelet ratio index
(APRI), the albumin-bilirubin grade (ALBI), and their
combinations. Furthermore, an independent multi-center
validation cohort (n = 161) was included to confirm the
findings concerning the prediction of postoperative
outcome.
Results. Higher ALBI, APRI, and APRI ? ALBI were
found in patients with postoperative morbidity (P = 0.001,
P = 0.064, P = 0.001, respectively), liver dysfunction
(LD) (P = 0.009, P = 0.012, P\ 0.001), or mortality
(P = 0.037, P = 0.045, P = 0.016), and APRI ? ALBI had
the highest predictive potential for LD (area under the
curve [AUC], 0.695). An increase in APRI ? ALBI was
observed during NeoCTx (P\ 0.001). Patients with longer
periods between NeoCTx and surgery showed a greater
decrease in APRI ? ALBI (P = 0.006) and a trend for
decreased CALI at surgery. A cutoff for APRI ? ALBI at
- 2.46 before surgery was found to identify patients with
CALI (P = 0.002) and patients at risk for a prolonged
hospital stay (P = 0.001), intensive care (P\ 0.001),
morbidity (P\ 0.001), LD (P\ 0.001), and mortality
(P = 0.021). Importantly, the study was able to confirm the
predictive potential of APRI ? ALBI for postoperative LD
and mortality in a multicenter validation cohort.
Conclusion. Determination of APRI ? ALBI before sur-
gery enables identification of high-risk patients for liver
resection. The combined score seems to dynamically reflect
CALI. Thus, APRI ? ALBI could be a clinically relevant
tool for optimizing timing of surgery in CRCLM patients
after NeoCTx.
Throughout the past decade, multimodal management of
patients with liver metastases of colorectal carcinoma
(CRCLM) has improved, leading to a significant
advancement in oncologic outcome.1,2 Liver resection (LR)
is considered the only potentially curative treatment of
colorectal liver metastases if complete resection can be
achieved. In this context, neoadjuvant chemotherapy
(NeoCTx) has proved to be efficient as a method to
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downsize liver metastases, which makes curative LR fea-
sible for a greater number of patients.3–5 Moreover, in
addition, findings have shown that patients with primary
resectable CRCLM benefit from NeoCTx.6–8 However,
preoperative treatment with oxaliplatin or irinotecan, the
most commonly used chemotherapeutic agents for patients
with CRCLM, is known to cause chemotherapy-associated
liver injury (CALI),9 ranging from steatosis to more severe
liver damage such as sinusoidal obstruction syndrome
(SOS) and chemotherapy-associated steatohepatitis
(CASH).10 Importantly, the development of postoperative
liver dysfunction (LD) has been associated with a higher
incidence of morbidity and mortality as well as the pres-
ence of CASH and SOS.11–15 Thus, the amount of NeoCTx
has to be optimally balanced between best oncologic effi-
cacy and least induced liver damage.16,17 Unfortunately,
assessment and staging of CALI remains challenging, and a
clinically applicable tool for noninvasive evaluation still is
missing.
Recently, a number of noninvasive scoring systems for
staging chronic liver disease have been established based
on routine laboratory parameters. Among these, the
aspartate-to-platelet-ratio index (APRI) and the albumin-
bilirubin grade (ALBI) have been shown to allow estima-
tion of liver function, as reflected by the Child–Pugh score
and indocyanine green (ICG) clearance.18–25
Although APRI was first introduced as a noninvasive
marker for hepatitis C-related liver fibrosis,26,27 it evolved
as a general marker for liver function in fibrotic and cir-
rhotic patients.28 In addition, findings have shown APRI to
be associated with SOS in patients after oxaliplatin-based
chemotherapy.29,30 Similarly, ALBI has been established
as a grading system for hepatic function, especially in
patients with hepatocellular carcinoma (HCC).31,32
Interestingly, studies have found both APRI and ALBI
to be predictors of postoperative outcome for patients
undergoing liver surgery.33–36 In particular, studies have
shown APRI to be predictive for the development of
postoperative LD in patients after major LR, and an asso-
ciation with the presence of SOS has been suggested.34,35
In parallel, studies have shown ALBI to be a predictive
marker for postoperative liver failure in patients undergo-
ing LR for HCC.37,38
This study aimed to assess the potential of APRI and
ALBI to predict a poor postoperative outcome for a
homogeneous cohort of CRCLM patients undergoing LR.
In addition, the study aimed to assess the potential pre-
dictive benefit of APRI and ALBI combined and to
elucidate the relation of both markers to NeoCTx.
METHODS
Patients
The study enrolled patients undergoing LR between
2001 and 2014 at the Medical University of Vienna who
had CRCLM. Data including routine blood parameters
were prospectively collected. Information on NeoCTx was
documented, and if applicable, blood parameters were
assessed before chemotherapy (preNeoCTx) and after
completion of chemotherapy (postNeoCTx). Blood was
taken from all patients before LR (preOP). Both APRI and
ALBI were calculated as specified in Fig. S1.
The current study aimed to assess CALI by a rigorous
pathologic examination of 170 patients. In addition, the
study included a validation cohort recruited at four differ-
ent institutions (Medical University of Vienna,
Rudolfstiftung Hospital Vienna, State Hospital Wiener
Neustadt, Inselspital, and University Hospital Bern). Based
on data from the exploration cohort, a sample size calcu-
lation was performed, and 158 patients were found to be
suitable for validation, based on the proportion of patients
with LD in the defined risk groups (a = 5%, b = 80%).
All the patients gave written informed consent. The
study was conducted in accordance with the Declaration of
Helsinki and approved by the institutional ethics committee
(#424/2010; #2032/2013).
Statistical Analysis
Statistical analyses, based on nonparametric tests, were
performed using SPSS (version 23; IBM Corp, Armonk,
NY, USA). A P value lower than 0.05 was considered
statistically significant. For more information on statistical
methods refer to the supplementary material.
RESULTS
Patient Demographics
Data from 339 patients with CRCLM were collected.
The data were prospectively recorded in the institutional
database. Patients were included independently of NeoCTx
regimen and grouped as ‘‘no NeoCTx,’’ ‘‘low hepatotoxi-
city’’ including fluorouracil-based regimen, ‘‘oxaliplatin,’’
‘‘irinotecan,’’ and ‘‘oxaliplatin ? irinotecan.’’ Baseline
characteristics are presented in Table S1.
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ALBI, APRI and APRI ? ALBI are Elevated in Patients
With Postoperative Morbidity, LD, or Mortality
First, the study aimed to validate previous reports on the
predictive potential of preoperative APRI and ALBI con-
cerning postoperative morbidity, LD, and mortality.
Accordingly, patients with postoperative morbidity showed
higher preoperative levels of ALBI (median no morbidity,
- 2.84; median morbidity, - 2.68; P = 0.001; Fig. 1a)
and a tendency toward higher levels of APRI (median no
morbidity, 0.33; median morbidity, 0.43; P = 0.064;
Fig. 1b). Similarly, patients who experienced postoperative
LD had higher values for ALBI (median no LD, - 2.82;
median LD, - 2.66; P = 0.009; Fig. 1c) and APRI (me-
dian no LD, 0.33; median LD, 0.49; P = 0.012; Fig. 1d)
before LR. Notably, seven patients died within 90 post-
operative days. Compared with the patients who did not die
postoperatively, the patients who died displayed higher
preoperative levels of ALBI (median no mortality, - 2.79;
median mortality, - 2.55; P = 0.037; Fig. 1e) and APRI
(median no mortality, 0.33; median mortality, 0.62;
P = 0.045; Fig. 1f).
Subsequently, we aimed to compare mathematical
combinations of APRI and ALBI and to assess the
differences between patients with and without morbidity,
LD, or mortality. According to our hypothesis, a summa-
tive combination of APRI and ALBI should be the most
effective variant because this combination should theoret-
ically increase the discriminatory capacity of each
individual marker. Indeed, the patients with postoperative
morbidity showed higher values of APRI ? ALBI already
before the operation (median no morbidity, - 2.48; median
morbidity, - 2.27; P = 0.001; Fig. 1g). This also was
found for patients who would experience LD (median no
LD, - 2.44; median LD, - 2.16; P\ 0.001; Fig. 1h) and
for patients who did not survive for 90 postoperative days
(median no mortality, - 2.41; median mortality, - 1.87;
P = 0.016; Fig. 1i). Notably, other mathematical combi-
nations were assessed but ultimately found to be of less or
no statistical significance, as illustrated in Fig. S2.
APRI and ALBI Combined Improves the Prognostic
Potential for Prediction of Postoperative LD
To compare the potential of APRI and ALBI alone with
that of both variables combined to discriminate between
patients with and without LD, receiver operating charac-
teristic (ROC) curve analysis was performed. Notably,
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FIG. 1 Albumin-bilirubin
grade (ALBI), aspartate
aminotransferase (AST)-to-
platelet ratio index (APRI), and
APRI ? ALBI in accordance
with clinical outcome after liver
resection. Levels of ALBI (a, c,
e), APRI (b, d, f), and
APRI ? ALBI (g, h, i) are
shown for patients with and
without postoperative morbidity
(a, b, g), for patients with and
without postoperative liver
dysfunction (LD) (c, d, h), and
for patients with and those
without postoperative mortality
(e, f, i). *P\ 0.05.
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comparable results were shown by ALBI (area under the
curve [AUC], 0.636; 95% confidence interval [CI],
0.552–0.720; P = 0.009) and APRI alone (AUC, 0.633;
95% CI, 0.532–0.734; P = 0.012). Still, APRI and ALBI
combined showed the highest discriminatory potential,
with an AUC of 0.695 (95% CI, 0.613–0.777; P\ 0.001).
Thus, further analysis was focused on APRI ? ALBI.
A Cutoff of APRI ? ALBI at - 2.46 Allows
Preoperative Risk Stratification of Patients Undergoing
Liver Resection
Based on the ROC curve of APRI ? ALBI for postop-
erative LD, a cutoff was identified using Youden’s J
statistic. This cutoff was found to be - 2.46. Accordingly,
the patients were divided into a low-risk group (APRI ?
ALBIlow, B 2.46) and a high-risk group (APRI ?
ALBIhigh,[ 2.46). For the patients above the cutoff, a
significantly higher incidences of prolonged hospitalization
([ 10 days) (APRI ? ALBIhigh 40.1% vs APRI ?
ALBIlow 20.5%; P\ 0.001; Fig. 2a), and prolonged
intensive care unit (ICU) stay ([ 3 days) (APRI ?
ALBIhigh 13.8% vs APRI ? ALBIlow 0.8%; P\ 0.001;
Fig. 2b) were observed. Furthermore, the patients in the
high-risk group displayed significantly higher incidences of
postoperative LD (APRI ? ALBIhigh 17.9% vs APRI ?
ALBIlow 3.1%; P\ 0.001; Fig. 2c) and morbidity
(APRI ? ALBIhigh 46.5% vs APRI ? ALBIlow 25.8%;
P\ 0.001; Fig. 2d).
Interestingly, only the patients in the APRI ? ALBIhigh
group experienced clinically relevant postoperative LD
graded according to the International Study Group of Liver
Surgery (ISGLS) criteria (grades B and C), as visualized in
Fig. S3a. Similarly, severe postoperative complications
classified higher than Dindo grade 4 were exclusively
observed in high-risk patients according to APRI ? ALBI
(Fig. S3b). Ultimately, only patients in the high-risk group
died within 90 postoperative days (P = 0.021; Fig. 2e).
Notably, the study was able to confirm the prediction of a
poor outcome for both minor and major LR (Fig. S4).
Prediction of Postoperative LD Using APRI ? ALBI is
Independent of Other Variables and Confounders
To test for the independence of the proposed cutoff from
other predictors of LD and to identify potential con-
founding factors, multivariable analysis was performed
(Table S2). However, after the proposed cutoff for
APRI ? ALBI, the extent of resection, the alkaline phos-
phatase (AP) level, the gamma-glutamyl transferase (GGT)
level, and the retention rate after 15 min for ICG clearance
were entered into the multivariable model, only the pro-
posed cutoff (P = 0.002; odds ratio [OR], 5.501; 95% CI,
1.822–16.606) and preoperative gGT (P\ 0.001; OR,
1.006; 95% CI, 1.003–1.010) remained as significant
independent variables after stepwise forward selection.
Patients Treated with Neoadjuvant Chemotherapy
Display Higher Levels of Preoperative APRI ? ALBI
Because APRI ? ALBI were associated with postoper-
ative outcome, we aimed to investigate the underlying
etiology behind elevated levels of APRI ? ALBI.
Increased levels of APRI ? ALBI were observed in
patients treated with NeoCTx (median no NeoCTx,
- 2.53; median NeoCTx, - 2.39; P = 0.028; Fig. 3a).
Intriguingly, patients treated with chemotherapeutic agents
with lower hepatotoxicity also showed significantly lower
scores than the patients treated with commonly used regi-
mens (i.e., based on oxaliplatin, irinotecan, or a
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combination of both) (median low hepatotoxicity, - 2.64;
median hepatotoxic NeoCTx, - 2.37; P = 0.038; Fig. 3b).
Notably, APRI ? ALBI did not differ significantly
between the patients without NeoCTx and the patients
treated with fewer hepatotoxic agents (P = 0.641; Fig. 3c).
Strikingly, a clear distinction was observed between the
patients treated with different types of common regimens
and the patients treated with less or no hepatotoxic
NeoCTx (mean no NeoCTx, - 2.53; mean irinotecan,
- 2.43 [P = 0.616]; median oxaliplatin, - 2.38
[P = 0.011]; median oxaliplatin ? irinotecan, - 2.01
[P = 0.019]; median low hepatotoxicity, - 2.64
[P = 0.369, P = 0.024, P = 0.044, respectively]; Fig. 3c).
Patients with CALI Can be Identified Using
the Proposed Cutoff for APRI ? ALBI
Next, the relation of the proposed cutoff for CALI was
assessed. A significantly higher prevalence of CALI irre-
spective of type was observed for the patients in the high-
risk group (APRI ? ALBIhigh 32% vs APRI ? ALBIlow
10.3%; P = 0.002; Fig. 3d). The subtypes of CALI,
patients in the high-risk group were found more frequently
to display severe steatosis (APRI ? ALBIhigh 18.6% vs
APRI ? ALBIlow 3.4%; P = 0.007; Fig. 3e) and steato-
hepatitis, both when graded according to the non-alcoholic
fatty liver disease activity score (NAS)39 (APRI ?
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associated liver injury (CALI). Levels of APRI ? ALBI are shown
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ALBIhigh 13.5% vs APRI ? ALBIlow 3.4%; P = 0.041;
Fig. 3f) and according to Brunt et al.40 (APRI ? ALBIhigh
12.5% vs APRI ? ALBIlow 1.7%; P = 0.020; Fig. 3g).
Furthermore, a tendency toward a higher prevalence of
severe SOS was found for patients above the proposed
cutoff (APRI ? ALBIhigh 7.3% vs APRI ? ALBIlow 3.4%;
P = 0.325; Fig. 3h).
Levels of APRI ? ALBI Dynamically Change During
Neoadjuvant Chemotherapy and Allow Quantification
of Liver Function Recovery
To investigate a potential dynamic change of APRI ?
ALBI during NeoCTx, the score was assessed before
NeoCTx and directly after completion of the last cycle.
Indeed, levels of APRI ? ALBI were found to increase
significantly after NeoCTx (median preNeoCTx, - 2.60;
median postNeoCTx, - 2.27; P\ 0.001; Fig. 4a). This
increase persisted until the time of surgery (median pre-
NeoCTx, - 2.60; median preOP, - 2.40; P\ 0.001;
Fig. 4a). Importantly, a continuous decrease in APRI ?
ALBI with time between the last cycle of NeoCTx and
surgery could be observed. In particular, DAPRI ? ALBI
([APRI ? ALBI{preOP}] - [APRI ? ALBI {post-
NeoCTx)}), representing the recovery of APRI ? ALBI,
significantly correlated with the length of NeoCTx cessa-
tion before surgery (P = 0.042, R = - 0.305). Indeed, the
decrease in APRI ? ALBI was more pronounced for the
patients with a period of 6 to 9 weeks after NeoCTx than
for the patients who had a break shorter than 3 weeks
before LR (median 0–3 weeks break, 0.35; median
7–9 weeks break, - 0.11; P = 0.006; Fig. 4b). Notably,
this decrease in APRI ? ALBI over time was paralleled by
a decreased prevalence of CALI among the patients with a
longer cessation of NeoCTx before surgery (Fig. 4c).
APRI ? ALBI is a Reliable Marker for Postoperative
Outcome as Validated in an Independent Multicenter
Cohort
To confirm the obtained data regarding the predictive
potential of APRI ? ALBI for postoperative outcome, a
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multi-center validation cohort was investigated. This
analysis included 161 patients (Medical University of
Vienna [n = 32 patients], Rudolfstiftung Hospital Vienna
[n = 50 patients], State Hospital Wiener Neustadt [n = 48
patients], and Inselspital and University Hospital Bern
[n = 31 patients]; Table S3).
The patients were divided into risk groups according to
their preoperative APRI ? ALBI. The patients above the
cutoff of –2.46 for APRI ? ALBI showed a significantly
longer postoperative hospital stay (APRI ? ALBIhigh
47.8% vs APRI ? ALBIlow 28.4%; P = 0.015; Fig. 5a)
and a tendency toward a prolonged ICU stay (APRI ?
ALBIhigh 23.9% vs APRI ? ALBIlow 12.3%; P = 0.066;
Fig. 5b). Strikingly, the patients in the high-risk group
were found to have significantly higher incidences of
postoperative LD (APRI ? ALBIhigh 13.2% vs APRI ?
ALBIlow 1.2%; P = 0.003; Fig. 5c) and morbidity
(APRI ? ALBIhigh 45.6% vs APRI ? ALBIlow 28.9%;
P = 0.034; Fig. 5d). Ultimately, only patients in the high-
risk group died within 90 postoperative days (APRI ?
ALBIhigh 4.5% vs APRI ? ALBIlow 0.0%; P = 0.071;
Fig. 5e).
DISCUSSION
For a large fraction of patients with CRCLM, NeoCTx is
routinely used.3,6,7 Indeed, its beneficial effects have been
shown for both resectable and primarily unre-
sectable CRCLM.3,7,41 However, the development of CALI
and a concomitantly increased risk for postoperative
complications and LD remain drawbacks for NeoCTx.16
More importantly, reliable diagnosis and staging of CALI
remain a challenging task for clinicians. Indeed, radiologic
studies do not provide satisfactory information.42 Further-
more, proposed methods for identifying patients with
CALI, such as ICG clearance,43,44 are expensive and have
not found their way into clinical routine. Thus, liver biopsy
often is the examination of choice, but due to the high
degree of invasiveness, it is reserved for high-risk patients
with suspicion of severe liver damage. This leaves the
majority of patients undergoing LR after NeoCTx without
adequate preoperative assessment for CALI.
Intriguingly, liver biopsy and histopathologic examina-
tion have been shown to have low sensitivity for most types
of CALI.45 In a prospective study, Vigano` et al.45 aimed to
assess the sensitivity and accuracy of preoperative liver
biopsies versus examination of resected liver parenchyma
for CALI detection. Notably, only steatosis could be reli-
ably detected, with a sensitivity of 88.9% and an accuracy
of 93%. Importantly, diagnosis of SOS had an accuracy of
only 63% and a sensitivity of only 21.1%. Similarly,
steatohepatitis was diagnosed correctly in only 78% of
cases and with a sensitivity of only 21.1%. This suggests
that percutaneous liver biopsy does not suitably reflect the
actual pathophysiologic degree of liver damage.
Strikingly, using the combination of APRI ? ALBI, we
were able to identify CALI (as evaluated in the surgical
specimen) with a much higher sensitivity. Whereas severe
steatosis was detected with a sensitivity of 90%, the cutoff
was able to identify SOS with a sensitivity of 77.8%, and
detection of CASH showed sensitivities of 86.7% (NAS
C 4) and 92.3% (Brunt = 3). This favors the use of
APRI ? ALBI as a noninvasive tool for the sensitive
identification of CALI before surgery.
Interestingly, the patients in the high-risk group had a
significantly higher prevalence of severe steatosis and
CASH and a tendency toward an increased prevalence of
SOS. The was paralleled by a substantially higher inci-
dence of adverse clinical outcomes. Importantly, the
gathered data could be confirmed in an independent multi-
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center cohort of CRCLM patients undergoing LR at four
institutions. Accordingly, this leads to the suggestion that
APRI ? ALBI is able to stratify patients as those with
clinically relevant forms of CALI and those with only
slightly injured livers after NeoCTx.
Most importantly, the current study introduced
APRI ? ALBI as a useful tool for timing LR after
NeoCTx. We present solid data on the increase in
APRI ? ALBI during NeoCTx, suggesting a direct corre-
lation between the marker and induced liver damage.
Interestingly, this increase was not affected by the number
of NeoCTx cycles administered (R = - 0.115; P = 0.474),
suggesting that the susceptibility of patients to the devel-
opment of CALI might be more relevant than the duration
of NeoCTx itself.
Furthermore, a decrease in APRI ? ALBI during the
time of chemotherapy cessation before surgery was
observed. Indeed, this finding is consistent with recent
reports on the amelioration of CALI after chemotherapy
cessation.46 Correspondingly, APRI ? ALBI might be a
relevant tool for timing and postponement of LR. Indeed,
sequential assessment of APRI ? ALBI might allow
dynamic monitoring of CALI and hence potentially delay
surgery until the liver has adequately recovered. Although
high-risk patients according to APRI ? ALBI were shown
to have severely reduced postoperative outcome, a transi-
tion to the low-risk group after a certain period might
prevent the patient from these complications. Hence,
evaluation of APRI ? ALBI could be used to guide the
physician’s decision concerning when to operate on a
patient. However, the exact time frame might differ
between patients, which makes fine-meshed monitoring of
this marker essential for high-risk patients.
In conclusion, evaluation of APRI ? ALBI represents
an easy instrument for preoperative risk stratification of
patients undergoing LR after NeoCTx. Because this marker
is based on routine laboratory parameters, it is easily
assessable and can readily be implicated in clinical routine.
Notably, the summative combination of APRI and ALBI
was found to improve the predictive potential compared
with both scores assessed individually. Furthermore, eval-
uation of APRI ? ALBI seems to allow personalized
scheduling of LR after completion of NeoCTx. Ultimately,
this might help to reduce the incidence of chemotherapy-
associated complications after LR.
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